Stock Price Forecast

Jan. 18, 2019


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading TESARO, Inc. chart...

About the Company

Develops supportive care products for cancer patients

Please visit http://www.tesarobio.com for more information about the company.

Sector

Health Technology

Industry

Biotechnology

Employees

715

CEO

Leon O. Moulder

Exchange

NASDAQ

Website

http://www.tesarobio.com

$219M

Total Revenue

715

Employees

$4B

Market Capitalization

-6.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TSRO News

GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro

5y ago, source: TheStreet.com

GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug specialists Tesaro for around $5.1 billion. GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug ...

RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer

1mon ago, source: EurekAlert!

The RUBY Part 2 trial, sponsored by Tesaro Inc., a GSK group company, is a phase 3, randomized, double-blind, multicenter, placebo-controlled study. Eligible patients with primary advanced stage ...

Gilbert H Kliman's Net Worth

7d ago, source: Benzinga.com

Who is Gilbert H Kliman? Gilbert H Kliman has an estimated net worth of $887 Million. This is based on reported shares across multiple companies, which include AVEDRO INC, TESARO, Inc ...

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

7y ago, source: TheStreet.com

Correction: Tesaro's PARP inhibitor niraparib demonstrated a median PFS of 21 months in recently presented clinical trial, not 25 months as a previous version of this story stated. The story ...

Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer

16d ago, source: EurekAlert!

Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...

David M Mott's Net Worth

6d ago, source: Benzinga.com

Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...

GSK presents positive results from RUBY phase III trial of Jemperli to treat primary advanced or recurrent endometrial cancer at SGO 2024 meeting

1mon ago, source: Pharmabiz

Jemperli?was discovered by AnaptysBio, Inc. and licensed to Tesaro, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ...

Welcome to Inc.'s Directory of B2B Excellence

2mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

Etsy Inc.

2d ago, source: Wall Street Journal

1 Day ETSY -0.46% DJIA 0.67% S&P 500 0.87% Retail/Wholesale 0.37% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

About Inc.com | Everything You Need to Know to Grow and Start Your Business

12y ago, source: Inc

Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...

MPW Medical Properties Trust, Inc.

5d ago, source: Seeking Alpha

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama ...

Macy's, Inc. (M)

5d ago, source: Yahoo Finance

Vanguard Small Cap Value Index Fund 4.81M Dec 31, 2023 1.75% 89,121,520 Vanguard Extended Market Index Fund 4.05M Dec 31, 2023 1.47% 75,050,783 Avantis U.S. Small Cap Value Fund 3.32M Dec 31, 2023 ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...